Research programme: cystic fibrosis-associated infections therapy - Helix BioMedix
Latest Information Update: 17 Oct 2008
Price :
$50 *
At a glance
- Originator Helix BioMedix
- Class Peptides
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cystic fibrosis-associated respiratory tract infections
Most Recent Events
- 13 Apr 2006 Preclinical trials in Cystic fibrosis-associated respiratory tract infections in USA (Inhalation)
- 13 Apr 2006 Preclinical trials in Cystic fibrosis-associated respiratory tract infections in USA (Intratracheal)